Potential serotonergic agents for the treatment of schizophrenia.
作者： Ricardo P. Garay , Michel Bourin , Evelyne de Paillette , Ludovic Samalin , Ahcène Hameg
DOI: 10.1517/13543784.2016.1121995
关键词: Serotonergic 、 Medical literature 、 Psychiatry 、 Medicine 、 Apathy 、 Clinical trial 、 Schizophrenia 、 Serotonin Agents 、 Cognition 、 Vabicaserin
摘要: ABSTRACTIntroduction: For the last 30 years, drugs targeting serotonin receptors (5-HTR) have been intensively investigated in schizophrenia. New 5-HTRs are under development patients with schizophrenia.Areas covered: In this review, authors describe recent clinical trials for schizophrenia selective serotonergic agents and provide an opinion on how can help to fulfil current treatment needs. Clinical were found US EU trial registries medical literature. Relevant 5-HTR antagonists active animal models of also analysed.Expert opinion: Antipsychotics reduce positive symptoms (delusions, hallucinations disordered thought), but undesirable side effects. Moreover, satisfactory negative (apathy, poverty speech, lack interest social interactions) cognitive dysfunction is currently not available. The 5-HT2CR full agonist vabicaserin s...
sci-hub.se 参考文章(89)
St??phane Laurent, Pierre Boutouyrie, Arterial stiffness and stroke in hypertension: Therapeutic implications for stroke prevention CNS Drugs. ,vol. 19, pp. 1- 11 ,(2005) , 10.2165/00023210-200519010-00001
Yeshwant Kurhe, Radhakrishnan Mahesh, Mechanisms linking depression co-morbid with obesity: An approach for serotonergic type 3 receptor antagonist as novel therapeutic intervention Asian Journal of Psychiatry. ,vol. 17, pp. 3- 9 ,(2015) , 10.1016/J.AJP.2015.07.007
A.K. Martin, B. Mowry, D. Reutens, G.A. Robinson, Executive functioning in schizophrenia: Unique and shared variance with measures of fluid intelligence. Brain and Cognition. ,vol. 99, pp. 57- 67 ,(2015) , 10.1016/J.BANDC.2015.07.009
CA Jones, DJG Watson, KCF Fone, Animal models of schizophrenia British Journal of Pharmacology. ,vol. 164, pp. 1162- 1194 ,(2011) , 10.1111/J.1476-5381.2011.01386.X
H MELTZER, M HUANG, In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems Progress in Brain Research. ,vol. 172, pp. 177- 197 ,(2008) , 10.1016/S0079-6123(08)00909-6
Peter R. Blower, Granisetron: relating pharmacology to clinical efficacy. Supportive Care in Cancer. ,vol. 11, pp. 93- 100 ,(2003) , 10.1007/S00520-002-0410-Z
Anthony J. Rothschild, The Evidence-based Guide to Antipsychotic Medications ,(2009)
Oliver Stiedl, Elpiniki Pappa, Åsa Konradsson-Geuken, Sven Ove Ögren, The role of the serotonin receptor subtypes 5-HT1A and 5-HT7 and its interaction in emotional learning and memory Frontiers in Pharmacology. ,vol. 6, pp. 162- 162 ,(2015) , 10.3389/FPHAR.2015.00162
Sharon Rosenzweig-Lipson, Thomas A. Comery, Karen L. Marquis, Jonathan Gross, John Dunlop, 5-HT(2C) agonists as therapeutics for the treatment of schizophrenia. Handbook of experimental pharmacology. pp. 147- 165 ,(2012) , 10.1007/978-3-642-25758-2_6
R.P. Ward, M.W. Hamblin, J.E. Lachowicz, B.J. Hoffman, D.R. Sibley, D.M. Dorsa, Localization of serotonin subtype 6 receptor messenger RNA in the rat brain by in situ hybridization histochemistry. Neuroscience. ,vol. 64, pp. 1105- 1111 ,(1995) , 10.1016/0306-4522(94)00439-C